What is HC Wainwright’s Forecast for ZNTL Q1 Earnings?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Zentalis Pharmaceuticals in a report released on Tuesday, November 11th. HC Wainwright analyst A. Maldonado expects that the company will post earnings of ($0.39) per share for the quarter. HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at ($0.45) EPS and Q4 2026 earnings at ($0.49) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.12.

ZNTL has been the subject of a number of other reports. Wedbush reissued a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Tuesday. Leerink Partners restated a “market perform” rating and set a $2.00 target price on shares of Zentalis Pharmaceuticals in a report on Tuesday. Wall Street Zen lowered shares of Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Wells Fargo & Company cut their price objective on Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating for the company in a research report on Thursday, August 7th. Finally, Morgan Stanley reduced their price objective on Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating for the company in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Zentalis Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $5.03.

Zentalis Pharmaceuticals Stock Down 1.5%

Shares of ZNTL stock opened at $1.32 on Wednesday. The stock has a 50-day simple moving average of $1.53 and a 200 day simple moving average of $1.45. The stock has a market capitalization of $95.37 million, a P/E ratio of -0.64 and a beta of 1.87. Zentalis Pharmaceuticals has a fifty-two week low of $1.01 and a fifty-two week high of $4.16.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC boosted its position in shares of Zentalis Pharmaceuticals by 150.6% in the first quarter. Acadian Asset Management LLC now owns 2,674,035 shares of the company’s stock worth $4,244,000 after buying an additional 1,606,802 shares during the period. Nuveen LLC purchased a new stake in Zentalis Pharmaceuticals in the 1st quarter worth about $807,000. Tybourne Capital Management HK Ltd. boosted its position in Zentalis Pharmaceuticals by 53.7% during the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company’s stock worth $1,715,000 after acquiring an additional 516,666 shares during the period. GSA Capital Partners LLP grew its stake in Zentalis Pharmaceuticals by 275.9% during the 1st quarter. GSA Capital Partners LLP now owns 541,975 shares of the company’s stock valued at $862,000 after acquiring an additional 397,805 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Zentalis Pharmaceuticals in the 1st quarter valued at about $81,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.